HK Stock Market Move | CHINFMINING(01258) closed near 5% higher, Qianbihu Southeast Mine main and auxiliary shafts have resumed production. It is estimated that the comprehensive copper production this year will be around 480,000 tons.
China Nonferrous Mining (01258) rose nearly 5% at the close, up 4.83% as of the press release, at HK$15.63, with a trading volume of HK$3.08 billion.
CHINFMINING (01258) rose nearly 5% in the final trading hours, rising 4.83% at the time of writing, closing at HK$15.63 with a trading volume of HK$308 million.
In terms of news, CHINFMINING announced that the main and auxiliary shafts of the Qianbihesoutheast mine will complete the repairs by December 2025, and the repair results meet expectations. The mine officially resumed production on January 1, 2026. In 2026, the company expects a total copper production of around 484,000 tons, including around 134,000 tons of cathode copper and 350,000 tons of blister copper/anode copper.
It is worth noting that CHINFMINING announced last month that it plans to further acquire 55% of the shares of SM Minerals company, equivalent to 64,700 shares, for a total consideration of $89 million. After this acquisition is completed, the company will hold a total of 70% of the shares of SM Minerals. The company is registered in Kazakhstan and mainly engaged in copper mining and enrichment, with the Balkhash North mine area having approximately 1.5 million tons of copper resources.
Related Articles

On January 13th, SUNNY OPTICAL (02382) spent HK$41,787,800 to repurchase 640,000 shares.

FIH (02038) spent 2.4951 million Hong Kong dollars to repurchase 132,000 shares on January 13th.

HENLIUS (02696): The Biologics License Application (BLA) for Hanbeite (Bevacizumab injection) has been accepted by the Food and Drug Administration (FDA) of the United States.
On January 13th, SUNNY OPTICAL (02382) spent HK$41,787,800 to repurchase 640,000 shares.

FIH (02038) spent 2.4951 million Hong Kong dollars to repurchase 132,000 shares on January 13th.

HENLIUS (02696): The Biologics License Application (BLA) for Hanbeite (Bevacizumab injection) has been accepted by the Food and Drug Administration (FDA) of the United States.

RECOMMEND

Institutions Bullish On Hong Kong Stocks As Spring Rally Builds; Domestic And Foreign Capital Increase ETF Allocations
13/01/2026

The Sword Over Hong Kong Stocks: IPO Peaks And Unlocking Waves
13/01/2026

Learning From History: The AI Investment Wave Likely To End This Year, But The Fed May Shield U.S. Stocks
13/01/2026


